Literature DB >> 2991071

Neutralizing antibody to hepatitis A virus in immune serum globulin and in the sera of human recipients of immune serum globulin.

J T Stapleton, R Jansen, S M Lemon.   

Abstract

We determined the titer of neutralizing antibody to hepatitis A virus in five lots of immune serum globulin and in the sera of human recipients of immune globulin using a new and sensitive procedure, the radioimmunofocus inhibition assay. The neutralizing antibody titer of four immune globulin lots ranged from 1:170,000 to 1:406,000, and was approximately 100-fold the antibody titer determined by radioimmunoassay. The neutralizing antibody titer of a Bureau of Biologics reference immunoglobulin was 1:794,000. Sera collected from 18 healthy men who had undergone prophylaxis with immune globulin (0.02 ml/kg body wt) were negative when tested by radioimmunoassay. However, 2 of 18 sera collected before administration of immune globulin and sera from all 18 men collected 3 and 55 days later contained detectable neutralizing antibody. The measurement of neutralizing antibody should prove useful for standardizing passive immunoprophylaxis against hepatitis A as well as for evaluating the potential efficacy of new hepatitis A virus vaccines.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2991071     DOI: 10.1016/0016-5085(85)90462-7

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  12 in total

1.  Antigenic and immunogenic properties of recombinant hepatitis A virus 14S and 70S subviral particles.

Authors:  J T Stapleton; V Raina; P L Winokur; K Walters; D Klinzman; E Rosen; J H McLinden
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

2.  Complete nucleotide sequence of an attenuated hepatitis A virus: comparison with wild-type virus.

Authors:  J I Cohen; B Rosenblum; J R Ticehurst; R J Daemer; S M Feinstone; R H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

3.  Mimicry of the immunodominant conformation-dependent antigenic site of hepatitis A virus by motifs selected from synthetic peptide libraries.

Authors:  S Mattioli; L Imberti; R Stellini; D Primi
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

4.  The hepatitis A virus polyprotein expressed by a recombinant vaccinia virus undergoes proteolytic processing and assembly into viruslike particles.

Authors:  P L Winokur; J H McLinden; J T Stapleton
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

5.  Successful passive and active immunization of cynomolgus monkeys against hepatitis E.

Authors:  S A Tsarev; T S Tsareva; S U Emerson; S Govindarajan; M Shapiro; J L Gerin; R H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

6.  Immunologic priming with recombinant hepatitis A virus capsid proteins produced in Escherichia coli.

Authors:  T F Powdrill; J M Johnston
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

7.  Safety and immunogenicity of an inactivated hepatitis A vaccine in children 2 to 5 years old.

Authors:  J Arístegui; J L Morales; R Dal-Ré; A González; M S Gallego; E Garrote
Journal:  Infection       Date:  1995 Sep-Oct       Impact factor: 3.553

8.  Recombinant hepatitis A virus antigen: improved production and utility in diagnostic immunoassays.

Authors:  F D LaBrecque; D R LaBrecque; D Klinzman; S Perlman; J B Cederna; P L Winokur; J Q Han; J T Stapleton
Journal:  J Clin Microbiol       Date:  1998-07       Impact factor: 5.948

9.  Clinical trial with inactivated hepatitis A vaccine and recommendations for its use.

Authors:  A J Tilzey; S J Palmer; S Barrow; K R Perry; H Tyrrell; A Safary; J E Banatvala
Journal:  BMJ       Date:  1992-05-16

10.  Neutralization escape mutants define a dominant immunogenic neutralization site on hepatitis A virus.

Authors:  J T Stapleton; S M Lemon
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.